Alan Maloney
  • Drug Development for Patients
  • Contact
  • PDF
  • Share on Twitter
  1. Welcome
  • Welcome
  • 1  Introduction
  • 2  My Motivation For This Book
  • 3  Why Patients Outcomes Must Come First
  • 4  A Brief History Of Drug Development; The Good, The Bad And The Ugly
  • 5  Dose-Response Trials; A Brief History And Overview Of Current Practices
  • 6  The Science; Why We Must Care About Dose, Pharmacokinetics, Pharmacodynamics And Utility
  • 7  Introduction To IIV In PK And Its Consequences To D-E-R Trial Design
  • 8  Introduction To IIV In PD And D-E-R Analysis As Evidence For Regulators
  • 9  Personalised Dosing; Patients Are Different
  • 10  Where Does Precision Medicine And Personalised Medicine Fit In?
  • 11  Dose-Response Modelling; Why We Need Integrated Analyses Across All Doses/Trials
  • 12  Introducing The Most Important Dose-Response Model
  • 13  Population and Individual Dose-Exposure-Responses, Therapeutic Windows and Maximum Tolerated Doses
  • 14  What Should Be The Role For Regulators?
  • 15  The Two Regulatory Approval Pathways; “Approval P” and “Approval I”
  • 16  The Two Development Strategies; “Strategy P” and “Strategy I”
  • 17  Changing How We Pay For Drugs; Value/Outcome-Based Pricing And Subscription-Based Pricing
  • 18  What Product Should Drug Companies Sell? (can be skipped)
  • 19  Adaptive Randomisation In Population D-E-R Trials; Why We Should Learn As We Go
  • 20  The Half-Time Summary; What Have We Learnt, And What Solutions Are Outstanding?
  • 21  Technical Sections To Write
  • 22  Conclusions
  • 23  Acknowledgements
  • Glossary
  • Contact

Drug Development for Patients

Personalised Dosing For All

Author

Alan Maloney PhD

Published

1 May 2023

Welcome

Modern drug development is failing patients; it is painfully outdated and desperately needs to change.

This book explains why we must put individual patient outcomes at the centre of drug development and regulatory approval.

It explains why “one-size-fits-all” dosing is unscientific and incorrect; our (heterogeneous) patients often suffer terribly because we persist with the same “simple” fixed-dose regimen for all. We must refocus drug development to be truly “patient centric” and deliver Personalised Dosing (i.e. dose individualisation). By chapter 4, you will understand that our patients are not “fields”.

The recent draft FDA guidance on dose optimisation in oncology and Project Optimus both aim to improve dosing in oncology; this is excellent, but the continued emphasis on “one-size-fits-all” dosing is incorrect. Thus I have decided to release this (work in progress) book will the goal to both convince and motivate all stakeholders (patients, regulators, pharma, payers) to support a patient focused, Drug Development For Patients paradigm.

These FDA initiatives must state that smart, science-based dose titration algorithms that deliver Personalised Dosing will lead to much better individual patient outcomes than any fixed-dose regimens. If we truly care about obtaining the best individual patient outcomes, we must embrace Personalised Dosing across all therapeutic areas.

After presenting the clear and compelling scientific arguments, I will ask you in the conclusion:

  • Are you a part of the problem, continuing to accept fixed-dose regimens because you are very familiar with “simple”, even though this leads to worse patient outcomes?

  • Or are you part of the solution, prepared to embrace Personalised Dosing because you truly care and want the best possible outcomes for our patients?

This is your choice. I hope by the end of this book you will be convinced to choose and actively advocate for the latter; many already do, but we need your voice too!

Hopefully we can all pull together and make it happen.

Happy reading!

Al Maloney 😀

1  Introduction
Copyright Alan Maloney, May 2023
  • Keep Me Updated!